A Personalized CLL Vaccine: NeoVax with Inhye Ahn, MD Dana-Farber Cancer Institute
This show will not be live-streamed. You can submit your questions in advance by April 25th by clicking the button "Notify when available."
Learn from Inhye Ahn, MD of Dana-Farber Cancer Institute, about a personalized vaccine against CLL called NeoVax that is being administered in a clinical trial to CLL patients not yet eligible to start standard therapies (watch and wait community). What if all you needed for your CLL treatment was a vaccine? Learn how NeoVax works, how it is being administered, and other important insights into this breakthrough therapy.
Jenny introduces the agenda of the event and featured speaker Dr. Inhye Ahn.
Jenny discusses the NeoVax clinical trial with Dr. Ahn and any pre-submitted patient questions.
Inhye Ahn, MD
Dr. Ahn is a member of the Faculty of Medicine at Dana-Farber Cancer Institute specializing in the care of patients with chronic lymphocytic leukemia (CLL). She earned her medical degree from Catholic University of Korea and completed residency at The Methodist Hospital in Houston, TX combined with laboratory research training at MD Anderson Cancer Center. She completed hematology/oncology fellowship training at the National Institutes of Health. Her research highlighted patterns and molecular mechanisms of resistance to BTK inhibitors and led to the development of a novel prognostic tool specific to CLL patients receiving targeted therapy. Her goal as an investigator is to develop innovative therapies and individualized care for patients with CLL.
Jennifer Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.